LON:HEMO

Hemogenyx Pharmaceuticals Interim Earnings Results & Report

Hemogenyx Pharmaceuticals logo
GBX 621 -69.50 (-10.07%)
As of 11:58 AM Eastern

Hemogenyx Pharmaceuticals reported Interim earnings on September 30, 2025. The company reported EPS of -GBX 0.83.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

Hemogenyx Pharmaceuticals EPS Results

Actual EPS
-GBX 0.83
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hemogenyx Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Hemogenyx Pharmaceuticals Interim Earnings FAQ

Hemogenyx Pharmaceuticals (LON:HEMO) reported earnings of -GBX 0.83 per share for Interim. The report was announced on Tuesday, September 30, 2025.

Hemogenyx Pharmaceuticals Earnings Headlines

Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
Prediction: NVDA will “snap back” on this date
Others paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.tc pixel
See More Hemogenyx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hemogenyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemogenyx Pharmaceuticals and other key companies, straight to your email.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals (LON:HEMO), a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

View Hemogenyx Pharmaceuticals Profile